0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Myasthenia Gravis - Epidemiology Forecast to 2028
Published Date: April 2019
|
Report Code: DELV-Epid-153
Home | Market Reports | Health
Myasthenia Gravis Epidemiology Forecast to 2028

Myasthenia Gravis - Epidemiology Forecast to 2028

Code: DELV-Epid-153
Report
April 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Myasthenia Gravis - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Myasthenia Gravis epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Myasthenia Gravis Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Myasthenia Gravis in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Myasthenia Gravis outlook. It also includes the explanation of changing trends of epidemiology outlining the Myasthenia Gravis scenario.

Myasthenia Gravis Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Myasthenia Gravis thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Myasthenia Gravis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Myasthenia Gravis Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Myasthenia Gravis

Key assessments
• Patient Segmentation in Myasthenia Gravis
• Myasthenia Gravis Risk & Burden
• Factors driving growth in a specific Myasthenia Gravis patient population

1. Report Introduction
2. Myasthenia Gravis Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Myasthenia Gravis in 2016
2.2. Patient Share Distribution of Myasthenia Gravis in 2028
3. Disease Background and Overview: Myasthenia Gravis
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Myasthenia Gravis in 7MM
4.3. Total Prevalent/ Incident Patient Population of Myasthenia Gravis in 7MM – By Countries
5. Epidemiology of Myasthenia Gravis by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Myasthenia Gravis
5.1.3. Sub-Type Specific cases of the Myasthenia Gravis *
5.1.4. Sex- Specific Cases of the Myasthenia Gravis *
5.1.5. Diagnosed Cases of the Myasthenia Gravis
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Myasthenia Gravis
5.4.3. Sub-Type Specific cases of the Myasthenia Gravis *
5.4.4. Sex- Specific Cases of the Myasthenia Gravis *
5.4.5. Diagnosed Cases of the Myasthenia Gravis
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Myasthenia Gravis
5.5.3. Sub-Type Specific cases of the Myasthenia Gravis *
5.5.4. Sex- Specific Cases of the Myasthenia Gravis *
5.5.5. Diagnosed Cases of the Myasthenia Gravis
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Myasthenia Gravis
5.6.3. Sub-Type Specific cases of the Myasthenia Gravis *
5.6.4. Sex- Specific Cases of the Myasthenia Gravis *
5.6.5. Diagnosed Cases of the Myasthenia Gravis
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Myasthenia Gravis
5.7.3. Sub-Type Specific cases of the Myasthenia Gravis *
5.7.4. Sex- Specific Cases of the Myasthenia Gravis *
5.7.5. Diagnosed Cases of the Myasthenia Gravis
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Myasthenia Gravis
5.8.3. Sub-Type Specific cases of the Myasthenia Gravis *
5.8.4. Sex- Specific Cases of the Myasthenia Gravis *
5.8.5. Diagnosed Cases of the Myasthenia Gravis
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Myasthenia Gravis
5.9.3. Sub-Type Specific cases of the Myasthenia Gravis *
5.9.4. Sex- Specific Cases of the Myasthenia Gravis *
5.9.5. Diagnosed Cases of the Myasthenia Gravis
6. Unmet Needs of the Myasthenia Gravis
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables :

Table 1: Total Prevalent/Incident Cases of the Myasthenia Gravis in 7MM
Table 2: Total Prevalent/Incident Cases of the Myasthenia Gravis in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Myasthenia Gravis in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Myasthenia Gravis in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Myasthenia Gravis in United States (2016-2028)*
Table 6: Diagnosed Cases of the Myasthenia Gravis in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Myasthenia Gravis in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Myasthenia Gravis in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Myasthenia Gravis in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Myasthenia Gravis in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Myasthenia Gravis in France (2016-2028)
Table 12: Sub-Type Specific cases of the Myasthenia Gravis in France (2016-2028) *
Table 13: Sex- Specific Cases of the Myasthenia Gravis in France (2016-2028) *
Table 14: Diagnosed Cases of the Myasthenia Gravis in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Myasthenia Gravis in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Myasthenia Gravis in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Myasthenia Gravis in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Myasthenia Gravis in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Myasthenia Gravis in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Myasthenia Gravis in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Myasthenia Gravis in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Myasthenia Gravis in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Myasthenia Gravis in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Myasthenia Gravis in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Myasthenia Gravis in UK (2016-2028) *
Table 26: Diagnosed Cases of the Myasthenia Gravis in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Myasthenia Gravis in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Myasthenia Gravis in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Myasthenia Gravis in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Myasthenia Gravis in Japan (2016-2028)

Listof figures :

Figure 1: Total Prevalent/Incident Cases of the Myasthenia Gravis in 7MM
Figure 2: Total Prevalent/Incident Cases of the Myasthenia Gravis in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Myasthenia Gravis in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Myasthenia Gravis in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Myasthenia Gravis in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Myasthenia Gravis in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Myasthenia Gravis in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Myasthenia Gravis in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Myasthenia Gravis in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Myasthenia Gravis in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Myasthenia Gravis in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Myasthenia Gravis in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Myasthenia Gravis in France (2016-2028) *
Figure 14: Diagnosed Cases of the Myasthenia Gravis in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Myasthenia Gravis in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Myasthenia Gravis in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Myasthenia Gravis in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Myasthenia Gravis in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Myasthenia Gravis in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Myasthenia Gravis in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Myasthenia Gravis in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Myasthenia Gravis in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Myasthenia Gravis in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Myasthenia Gravis in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Myasthenia Gravis in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Myasthenia Gravis in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Myasthenia Gravis in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Myasthenia Gravis in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Myasthenia Gravis in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Myasthenia Gravis in Japan (2016-2028)

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Bioinformatics Barcelona

RELATED REPORTS

China Diclofenac Sodium and Codeine Phosphate Tablets Market Report Forecast 2021 2027
China Diclofenac Sodium and Codeine Phosphate Tablets Market Report & Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-23N6694
Tue Oct 26 00:00:00 UTC 2021

Add to Cart

Global and Japan Plastic Bandages Market Insights Forecast to 2027
Global and Japan Plastic Bandages Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-7N7087
Tue Oct 26 00:00:00 UTC 2021

Add to Cart

China Equine Pharmaceuticals and Supplements Market Report Forecast 2021 2027
China Equine Pharmaceuticals and Supplements Market Report & Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-34V6752
Tue Oct 26 00:00:00 UTC 2021

Add to Cart

Global and United States Medical Diagnostic Ultrasonic Equipment Market Insights Forecast to 2027
Global and United States Medical Diagnostic Ultrasonic Equipment Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-29X6747
Mon Oct 25 00:00:00 UTC 2021

Add to Cart